ESC Professional Premium Access

Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review

Congress Session

About the speaker

Doctor Margaret Sketch

United Therapeutics Corporation, Research Triangle Park (United States of America)
0 follower

4 more presentations in this session

Efficacy and dose-response relationship of oral treprostinil in PAH patients on monotherapy or dual background therapy

Speaker: Doctor J. Barbera (Barcelona, ES)

Thumbnail

UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)

Speaker: Professor V. McLaughlin (Ann Arbor, US)

Thumbnail

Macitentan for pulmonary arterial hypertension related to repaired congenital heart disease: Real-world UK experience

Speaker: Doctor A. Constantine (London, GB)

Thumbnail

Human umbilical cord mesenchymal stem cells attenuate experimental pulmonary arterial hypertension

Speaker: Professor H. Dai (Kunming, CN)

Thumbnail

Access the full session

Treatment of pulmonary arterial hypertension: the old and the new

Speakers: Doctor M. Sketch, Doctor J. Barbera, Professor V. McLaughlin, Doctor A. Constantine, Professor H. Dai
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk